ArticleJournal of immunology (Baltimore, Md. : 1950)2008
Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Immunotherapeutic Strategies Targeting GD2-Expressing Malignancies.Advances in experimental medicine and biology · 2026Review
- Article
- GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies.Cancer drug resistance (Alhambra, Calif.) · 2022Article
- Phage Display-Based Nanotechnology Applications in Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2020Review
- Modulation of cell adhesion and migration through regulation of the immunoglobulin superfamily member ALCAM/CD166.Clinical & experimental metastasis · 2019Review
- Structural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody.Molecular & cellular proteomics : MCP · 2015Article
- Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01.PloS one · 2015Article
- Mimotope vaccination for epitope-specific induction of anti-VEGF antibodies.BMC biotechnology · 2013Article
- Tumor-Associated Glycans and Immune Surveillance.Vaccines · 2013Review
- Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.British journal of cancer · 2012Article
- Potential of peptides as inhibitors and mimotopes: selection of carbohydrate-mimetic peptides from phage display libraries.Journal of nucleic acids · 2012Article
- Mimotope ELISA for detection of broad spectrum antibody against avian H5N1 influenza virus.PloS one · 2011Article
- Mimotopes selected with a neutralizing antibody against urease B from Helicobacter pylori induce enzyme inhibitory antibodies in mice upon vaccination.BMC biotechnology · 2010Article
- Cancer vaccine with mimotopes of tumor-associated carbohydrate antigens.Immunologic research · 2010Review
- Bridging innate and adaptive antitumor immunity targeting glycans.Journal of biomedicine & biotechnology · 2010Review
- Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- RESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY.Current pediatric reviews · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
The GD2 ganglioside expressed on neuroectodermal tumor cells has been used as a target for passive and active immunotherapy in patients with malignant melanoma and neuroblastoma. We have reported that immunization of mice with a 47-LDA mimotope of GD2, isolated from a phage display peptide library with anti-GD2 mAb 14G2a, induces MHC class I-restricted CD8(+) T cell responses to syngeneic neuroblastoma tumor cells. The cytotoxic activity of the vaccine-induced CTLs was independent of GD2 expression, suggesting recognition of a novel tumor-associated Ag cross-reacting with 47-LDA. Glycan microarray and immunoblotting studies using 14G2a mAb demonstrated that this Ab is highly specific for the entire carbohydrate motif of GD2 but also cross-reacts with a 105 kDa glycoprotein expressed by GD2(+) and GD2(-) neuroblastoma and melanoma cells. Functional studies of tumor cells grown in three-dimensional collagen cultures with 14G2a mAb showed decreases in matrix metalloproteinase-2 activation, a process regulated by the 105 kDa-activated leukocyte cell adhesion molecule (ALCAM/CD166). A recombinant CD166 glycoprotein was shown to be recognized by 14G2a Ab and inhibition of CD166 expression by RNA interference ablated the cell sensitivity to lysis by 47-LDA-induced CD8(+) T cells in vitro and in vivo. The binding of 14G2a to CD166 was not disruptable by a variety of exo- and endo-glycosidases, implying recognition of a non-glycan epitope on CD166. These results suggest that the vaccine-induced CTLs recognize a 47-LDA cross-reactive epitope expressed by CD166, and reveal a novel mechanism of induction of potent tumor-specific cellular responses by mimotopes of tumor-associated carbohydrate Ags.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.